Elutia Inc. Class A Common Stock (ELUT)
Stock · NASDAQ · Health Care
$0.794as of 10/16/2026
Price chart
Active signals
ELUT Signal Track Record
How signals performed across all stocks →What ELUT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -6.0% | 44% | October 1, 2026 |
| Bollinger Band Breakout | 22 | -5.4% | 41% | May 20, 2026 |
| Bollinger Band Breakdown | 20 | +2.6% | 65% | July 29, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +5.2% | 58% | August 14, 2026 |
| Any 20-session window (baseline) | -1.3% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 25
- Website
- elutia.com/
Fundamentals
- 1-day range
- $0.72$0.805
- Market cap
- $38.95M
- P/E (trailing)
- 0.67
- P/E (forward)
- -0.66
- EPS (trailing)
- $1.22
- Dividend yield
- —
- Beta
- 0.96
- Avg. volume
- 186.4K
How Elutia Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Elutia Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- ELUTElutia Inc. Class A Common Stock$0.794▲ 0.63%Market cap $38.95MP/E 0.67$0.5$1.39
- DYAIDyadic International Inc. Common Stock$0.41▼ 2.38%Market cap $37.17MP/E —$0.3401$1.6
- TVGNTevogen Inc. Common Stock$7.07▼ 0.14%Market cap $41.58MP/E —$3.64$39
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
- ENGNWenGene Therapeutics Inc. Warrants$0.17▲ 1.19%Market cap $33.75MP/E —$0.1113$4.2
- ESLAEstrella Immunopharma Inc. Common Stock$0.43▼ 19.63%Market cap $32.10MP/E —$0.295$3.15
- MGXMetagenomi Therapeutics Inc. Common Stock$0.784▼ 7.22%Market cap $46.68MP/E —$0.86$3.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELUT Elutia Inc. Class A Common Stock | $38.95M | 0.67 | $0.794 | ▲ 0.63% | $0.5$1.39 |
| DYAI Dyadic International Inc. Common Stock | $37.17M | — | $0.41 | ▼ 2.38% | $0.3401$1.6 |
| TVGN Tevogen Inc. Common Stock | $41.58M | — | $7.07 | ▼ 0.14% | $3.64$39 |
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
| ENGNW enGene Therapeutics Inc. Warrants | $33.75M | — | $0.17 | ▲ 1.19% | $0.1113$4.2 |
| ESLA Estrella Immunopharma Inc. Common Stock | $32.10M | — | $0.43 | ▼ 19.63% | $0.295$3.15 |
| MGX Metagenomi Therapeutics Inc. Common Stock | $46.68M | — | $0.784 | ▼ 7.22% | $0.86$3.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- C. Randal Mills · June 21, 2026 · Option Exercise22.5K
- C. Randal Mills · June 21, 2026 · Tax Withholding8.1K @ $1.06
- David Colpman · June 11, 2026 · Grant106.4K
- Brigid Makes · June 11, 2026 · Grant106.4K
- Guido J. Neels · June 11, 2026 · Grant106.4K
- Kevin Rakin · June 11, 2026 · Grant159.6K
- Michelle LeRoux Williams · June 10, 2026 · Option Exercise12.5K
- Michelle LeRoux Williams · June 10, 2026 · Tax Withholding4.3K @ $1.04
- C. Randal Mills · June 10, 2026 · Option Exercise27.1K
- C. Randal Mills · June 10, 2026 · Tax Withholding9.7K @ $1.04
- Matthew Ferguson · June 10, 2026 · Option Exercise12.5K
- Matthew Ferguson · June 10, 2026 · Tax Withholding4.5K @ $1.04
- Kevin Rakin · June 1, 2026 · J50.0K
- Kevin Rakin · June 1, 2026 · Gift70.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 15.11M
- Total value held
- $15.80M
- Institutional holders
- 33
- Unknown3.60M
- Unknown3.18M
- Unknown2.56M
- Unknown2.50M
- Unknown1.02M
- Unknown756.9K
- Unknown293.4K
- Unknown249.0K
- Unknown165.1K
- Unknown122.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.